Preclinical in vivo validation of the RAD51 test for identification of homologous recombination-deficient tumors and patient stratification

PARP inhibitors (PARPi) are approved drugs for platinum-sensitive, high-grade serous ovarian cancer (HGSOC) and for breast (BC), prostate, and pancreatic cancers (PaC) harboring genetic alterations impairing homologous recombination repair (HRR). Detection of nuclear RAD51 foci in tumor cells is a m...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Res
Huvudupphovsmän: Pellegrino, Benedetta, Herencia-Ropero, Andrea, Llop-Guevara, Alba, Pedretti, Flaminia, Moles-Fernández, Alejandro, Viaplana, Cristina, Villacampa, Guillermo, Guzmán, Marta, Rodríguez, Olga, Grueso, Judit, Jiménez, Jose, Arenas, Enrique J., Degasperi, Andrea, Dias, João M. L., Forment, Josep V., O’Connor, Mark J., Déas, Olivier, Cairo, Stefano, Zhou, Yinghui, Musolino, Antonino, Caldas, Carlos, Nik-Zainal, Serena, Clarke, Robert B., Nuciforo, Paolo, Díez, Orland, Serres-Créixams, Xavier, Peg, Vicente, Espinosa-Bravo, Martín, Macarulla, Teresa, Oaknin, Ana, Mateo, Joaquin, Arribas, Joaquín, Dienstmann, Rodrigo, Bellet, Meritxell, Oliveira, Mafalda, Saura, Cristina, Gutiérrez-Enríquez, Sara, Balmaña, Judith, Serra, Violeta
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2022
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7612637/
https://ncbi.nlm.nih.gov/pubmed/35425960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-21-2409
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk